profit from every $100 of sales.
$0$100
Spero Therapeutics
$1.07+3.88% today
-56.5% in 1 year
1-year low $1.021-year high $2.98
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $7.27 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Spero Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $48.6 million in 2022 to $59.6 million in 2025, with $8.57 million of profit last year.
SalesProfit
Spero Therapeutics vs. similar companies
Spero Therapeutics grows the slowest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Spero Therapeutics | 7.3× · Cheap | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Spero Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 49 | 97 | 27 | 60 | |
| – | – | – | – | |
| -31 | 27 | -72 | 7 | |
| -43 | 27 | -72 | 7 | |
| -46 | 23 | -69 | 9 | |
| -1.23 | 0.43 | -1.27 | 0.15 | |
| – | – | – | – | |
| -62.9% | 27.7% | -264.6% | 12.0% | |
| -95.5% | 23.6% | -250.3% | 14.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 125 | 182 | 111 | 69 |
| Cash | 109 | 76 | 53 | 40 |
| Total debt | 7 | 6 | 4 | 3 |
| Total liabilities | 49 | 75 | 64 | 10 |
| 76 | 107 | 46 | 59 | |
| 38 | 53 | 54 | 59 | |
| -41.9% | 18.8% | -113.6% | 9.1% | |
| -61.1% | 21.3% | -148.7% | 14.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -8 | -33 | -23 | -13 | |
| – | – | – | – | |
| -8 | -33 | -23 | -13 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 9 | 8 | 8 | 4 |
Valuation
- 7.3×
- 1.6×
- –
- 2.4×
- 1.0×
- –
- 3.5×
- -20.3%
- 13.8%
- 0.0%
Profitability
- 77.5%
- 12.0%
- 14.4%
- 9.1%
- -0.0%
- -50.4%
- 22.5%
- 12.4%
- -0.0%
- 63.7%
Growth
- +7.1%
- –
- +46.2%
- –
- +16.0%
Financial health
- -6.8×
- 0.05
- 4.2%
- –
- 7.59
- 7.59
- 0.88
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 37%of 948
Top 42%of 871
Top 5%of 560
Bottom 35%of 868
Bottom 4%of 985
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.13 | -0.18 | +27.8% |
| Mar 26, 2026 | 0.53 | -0.20 | +365.0% |
| Nov 13, 2025 | -0.13 | -0.25 | +48.0% |
| Aug 12, 2025 | -0.03 | -0.38 | +92.1% |
| May 13, 2025 | -0.25 | -0.55 | +54.5% |
| Mar 27, 2025 | -0.38 | -0.35 | −8.6% |
| Nov 14, 2024 | -0.32 | -0.27 | −18.5% |
| Aug 5, 2024 | -0.33 | -0.35 | +5.7% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
3/7Passes 3 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
46No pass
Benjamin Graham
67Pass
Philip Fisher
47No pass
Peter Lynch
64Pass
Joel Greenblatt
60Pass
Charlie Munger
45No pass
Terry Smith
38No pass
Questions about Spero Therapeutics
Is Spero Therapeutics a good stock to buy?
A solid business, and the price looks low. 3 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Spero Therapeutics AI analysis
What does Spero Therapeutics do?
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. It is in Biotechnology.
Does Spero Therapeutics pay a dividend?
No. Spero Therapeutics does not pay a dividend at the moment.
Is Spero Therapeutics stock halal?
No. Spero Therapeutics does not pass our halal screen: its cash and confirmed interest-bearing investments are 65% of its market value, at or above the 33% limit. How we check
How has Spero Therapeutics stock done over the past year?
Down 56.5% over the past twelve months, to $1.07. It traded between $1.02 and $2.98 and is 64.1% below its high.
Who are Spero Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Spero Therapeutics's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.